FULC
Fulcrum Therapeutics, Inc.
Biotechnology
Market Cap$372M
5Y Perf.-65.4%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
FULC vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.-58.8%
FULC vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | FULC | DBVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $372M | $1712.35T |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-76M | $-168M |
| Total Debt | $6M | $22M |
| Cash & Equiv. | $198M | $194M |
FULC vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
FULC
DBVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Fulcrum Therapeutic… (FULC) | 100 | 34.6 | -65.4% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: FULC vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: FULC and DBVT are tied at the top with 2 categories each — the right choice depends on your priorities. DBV Technologies S.A. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
FULC
Fulcrum Therapeutics, Inc.
The Growth Play
FULC has the current edge in this matchup, primarily because of its strength in growth exposure and long-term compounding.
- Rev growth -100.0%, EPS growth -6.4%
- -49.0% 10Y total return vs DBVT's -87.0%
- Lower volatility, beta 1.40, Low D/E 1.8%, current ratio 27.40x
Best for: growth exposure and long-term compounding
DBVT
DBV Technologies S.A.
The Income Pick
DBVT is the clearest fit if your priority is income & stability and defensive.
- Dividend streak 0 yrs, beta 1.26
- Beta 1.26, current ratio 3.67x
- Beta 1.26 vs FULC's 1.40
Best for: income & stability and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | FULC | -100.0% revenue growth vs DBVT's -100.0% |
| Stability / Safety | DBVT | Beta 1.26 vs FULC's 1.40 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | DBVT | +110.4% vs FULC's +35.7% |
| Efficiency (ROA) | FULC | -26.3% ROA vs DBVT's -89.0% |
FULC vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLFULCLAGGINGDBVT
DBVTDBV Technologies S.A.
2leads
FULCFulcrum Therapeutics,…
2leads
6 Total Categories
CATEGORYLEADERvs DBVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DBVT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
FULC6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
FULC4/6
Risk & VolatilityBeta, volatility, and downside exposure
DBVT2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
FULC and DBVT operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | FULCFulcrum Therapeut… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$86M | -$112M |
| Net IncomeAfter-tax profit | -$76M | -$168M |
| Free Cash FlowCash after capex | -$64M | -$151M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +10.7% | +91.5% |
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — FULC and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | FULCFulcrum Therapeut… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $372M | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $181M | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | -5.83x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 1.25x | 0.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — FULC and DBVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
FULC leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
FULC delivers a -27.8% return on equity — every $100 of shareholder capital generates $-28 in annual profit, vs $-130 for DBVT. FULC carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to DBVT's 0.13x. On the Piotroski fundamental quality scale (0–9), DBVT scores 4/9 vs FULC's 3/9, reflecting mixed financial health.
| Metric | FULCFulcrum Therapeut… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | -27.8% | -130.2% |
| ROA (TTM)Return on assets | -26.3% | -89.0% |
| ROICReturn on invested capital | -36.2% | — |
| ROCEReturn on capital employed | -28.1% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.02x | 0.13x |
| Net DebtTotal debt minus cash | -$191M | -$172M |
| Cash & Equiv.Liquid assets | $198M | $194M |
| Total DebtShort + long-term debt | $6M | $22M |
| Interest CoverageEBIT ÷ Interest expense | — | -189.82x |
FULC leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
FULC leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in FULC five years ago would be worth $6,565 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs FULC's +35.7%. The 3-year compound annual growth rate (CAGR) favors FULC at 30.7% vs DBVT's 6.2% — a key indicator of consistent wealth creation.
| Metric | FULCFulcrum Therapeut… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | -37.0% | +4.9% |
| 1-Year ReturnPast 12 months | +35.7% | +110.4% |
| 3-Year ReturnCumulative with dividends | +123.4% | +19.7% |
| 5-Year ReturnCumulative with dividends | -34.4% | -69.1% |
| 10-Year ReturnCumulative with dividends | -49.0% | -87.0% |
| CAGR (3Y)Annualised 3-year return | +30.7% | +6.2% |
FULC leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
DBVT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
DBVT is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than FULC's 1.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 76.3% from its 52-week high vs FULC's 43.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | FULCFulcrum Therapeut… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.40x | 1.26x |
| 52-Week HighHighest price in past year | $15.74 | $26.18 |
| 52-Week LowLowest price in past year | $4.78 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +43.7% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 42.0 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 990K | 252K |
DBVT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates FULC as "Buy" and DBVT as "Buy". Consensus price targets imply 200.4% upside for FULC (target: $21) vs 131.8% for DBVT (target: $46).
| Metric | FULCFulcrum Therapeut… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $20.67 | $46.33 |
| # AnalystsCovering analysts | 16 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
DBVT leads in 2 of 6 categories (Income & Cash Flow, Risk & Volatility). FULC leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.
Best OverallFulcrum Therapeutics, Inc. (FULC)Leads 2 of 6 categories
Loading custom metrics...
FULC vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is FULC or DBVT a better buy right now?
Analysts rate Fulcrum Therapeutics, Inc.
(FULC) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — FULC or DBVT?
Over the past 5 years, Fulcrum Therapeutics, Inc.
(FULC) delivered a total return of -34. 4%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: FULC returned -49. 0% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — FULC or DBVT?
By beta (market sensitivity over 5 years), DBV Technologies S.
A. (DBVT) is the lower-risk stock at 1. 26β versus Fulcrum Therapeutics, Inc. 's 1. 40β — meaning FULC is approximately 11% more volatile than DBVT relative to the S&P 500. On balance sheet safety, Fulcrum Therapeutics, Inc. (FULC) carries a lower debt/equity ratio of 2% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.
04Which is growing faster — FULC or DBVT?
On earnings-per-share growth, the picture is similar: DBV Technologies S.
A. grew EPS -347. 5% year-over-year, compared to -637. 5% for Fulcrum Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — FULC or DBVT?
Fulcrum Therapeutics, Inc.
(FULC) is the more profitable company, earning 0. 0% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FULC leads at 0. 0% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — FULC leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — FULC or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is FULC or DBVT better for a retirement portfolio?
For long-horizon retirement investors, DBV Technologies S.
A. (DBVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Both have compounded well over 10 years (DBVT: -87. 0%, FULC: -49. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between FULC and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.